Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.
Herman JD, Wang C, Burke JS, Zur Y, Compere H, Kang J, Macvicar R, Taylor S, Shin S, Frank I, Siegel D, Tebas P, Choi GH, Shaw PA, Yoon H, Pirofski LA, Julg BD, Bar KJ, Lauffenburger D, Alter G. Herman JD, et al. Among authors: tebas p. Cell Rep Med. 2022 Nov 15;3(11):100811. doi: 10.1016/j.xcrm.2022.100811. Epub 2022 Oct 24. Cell Rep Med. 2022. PMID: 36351430 Free PMC article. Clinical Trial.
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
Pau AK, Aberg J, Baker J, Belperio PS, Coopersmith C, Crew P, Grund B, Gulick RM, Harrison C, Kim A, Lane HC, Masur H, Sheikh V, Singh K, Yazdany J, Tebas P; National Institutes of Health COVID-19 Treatment Guidelines Panel. Pau AK, et al. Among authors: tebas p. Ann Intern Med. 2021 Jan;174(1):93-95. doi: 10.7326/M20-6448. Epub 2020 Sep 25. Ann Intern Med. 2021. PMID: 32976026 Free PMC article.
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.
Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. Bhimraj A, et al. Among authors: tebas p. Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093/cid/ciae435. Online ahead of print. Clin Infect Dis. 2024. PMID: 39471458
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.
Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, Ridzon R, Masur H, Lane HC; NIH COVID-19 Treatment Guidelines Panel; Adimora AA, Baker J, Kreuziger LB, Bedimo R, Belperio P, Bhalla A, Burgess T, Campbell D, Cantrill S, Chew K, Chiotos K, Coopersmith C, Davey R, Dzierba A, Eisnor D, Eschenauer G, Francis J, Gallagher J, Glidden D, Goldenberg N, Grund B, Han A, Hardy E, Harrison C, Henderson L, Higgs E, Hinkson C, Hughes B, Johnson S, Keller M, Kim A, Knight R, Kuriakose S, Lennox J, Lerner A, Levy M, Li J, MacBrayne C, Martin G, Nadig N, Nason M, Patel P, Pavia A, Proschan M, Schulert G, Seam N, Sheikh V, Simpson S, Singh K, Swindells S, Tien P, Uyeki T, Waghmare A, Wolfe C, Yazdany J, Aberg J. Gulick RM, et al. Among authors: tebas p. Ann Intern Med. 2024 Nov;177(11):1547-1557. doi: 10.7326/ANNALS-24-00464. Epub 2024 Oct 1. Ann Intern Med. 2024. PMID: 39348691 Free article.
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Evering TH, et al. EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39252866 Free PMC article.
The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis.
Lee MJ, Eason M, Castagna A, Laura G, De Scheerder MA, Riley J, Tebas P, Gunst J, Søgaard O, Florence E, Kroon E, De Souza M, Mothe B, Caskey M, Fidler S. Lee MJ, et al. Among authors: tebas p. J Int AIDS Soc. 2024 Aug;27(8):e26349. doi: 10.1002/jia2.26349. J Int AIDS Soc. 2024. PMID: 39155436 Free PMC article.
Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center.
Hamilton KW, Hua E, Dutcher L, Fernandez Lynch H, Junker P, Doucette AG, Werner D, Kannel EZ, Civitello T, Gabriel P, Ahya VN, Jacobs DA, Garfall A, Pratz K, Degnan KO, Blumberg EA, Capozzi D, Craig E, Takach P, Payne AS, Geara A, Koenig H, Holzman L, Tebas P. Hamilton KW, et al. Among authors: tebas p. Open Forum Infect Dis. 2024 Jul 10;11(8):ofae388. doi: 10.1093/ofid/ofae388. eCollection 2024 Aug. Open Forum Infect Dis. 2024. PMID: 39100528 Free PMC article.
Cloning and functional characterization of novel human neutralizing anti-interferon-alpha and anti-interferon-beta antibodies.
Papasavvas E, Lu L, Fair M, Oliva I, Cassel J, Majumdar S, Mounzer K, Kostman JR, Tebas P, Bar-Or A, Muthumani K, Montaner LJ. Papasavvas E, et al. Among authors: tebas p. bioRxiv [Preprint]. 2024 May 5:2024.05.05.591636. doi: 10.1101/2024.05.05.591636. bioRxiv. 2024. Update in: J Immunol. 2024 Sep 15;213(6):808-822. doi: 10.4049/jimmunol.2400265. PMID: 38746170 Free PMC article. Updated. Preprint.
294 results